StockData
Autolus Therapeutics plc logo

Autolus Therapeutics plc (AUTL) stock

AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)

Close on Nov 17, 2026Market cap $290.12MP/E –Yield –

Autolus Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Autolus Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$225.61M. For fiscal 2025 it was -$283.57M. The highest annual figure on record is -$9.85M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$283.57M–
FY2024Dec 31, 2024-$206.27M–
FY2023Dec 31, 2023-$145.59M–
FY2022Dec 31, 2022-$112.31M–
FY2021Dec 31, 2021-$117.86M–
FY2020Dec 31, 2020-$117.76M–
FY2018Sep 30, 2018-$31.54M–
FY2017Sep 30, 2017-$16.36M–
FY2016Sep 30, 2016-$9.85M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$25.07M–
Q1 FY2026CQ1 2026Mar 31, 2026-$65.32M–
Q4 FY2025CQ4 2025Dec 31, 2025-$67.32M–
Q3 FY2025CQ3 2025Sep 30, 2025-$67.90M–
Q2 FY2025CQ2 2025Jun 30, 2025-$72.78M–
Q1 FY2025CQ1 2025Mar 31, 2025-$75.57M–
Q4 FY2024CQ4 2024Dec 31, 2024-$37.93M–
Q3 FY2024CQ3 2024Sep 30, 2024-$76.74M–
Q2 FY2024CQ2 2024Jun 30, 2024-$51.08M–
Q1 FY2024CQ1 2024Mar 31, 2024-$40.51M–
Q4 FY2023CQ4 2023Dec 31, 2023-$24.83M–
Q3 FY2023CQ3 2023Sep 30, 2023-$40.19M–
Q2 FY2023CQ2 2023Jun 30, 2023-$38.15M–
Q1 FY2023CQ1 2023Mar 31, 2023-$42.42M–
Q4 FY2022CQ4 2022Dec 31, 2022-$14.57M–
Q1 FY2021CQ1 2021Mar 31, 2021-$37.34M–
Q4 FY2020CQ4 2020Dec 31, 2020-$27.73M–
Q3 FY2020CQ3 2020Sep 30, 2020-$39.06M–
Q2 FY2020CQ2 2020Jun 30, 2020-$26.93M–
Q1 FY2020CQ1 2020Mar 31, 2020-$24.03M–
Q1 FY2018CQ4 2017Dec 31, 2017-$8.80M–

More Autolus Therapeutics figures

See a number that looks wrong?